Guangzhou Baiyunshan Pharmaceutical Holdings (00874) branch has obtained a supplementary application approval for a drug.

16:51 10/02/2026

Baiyunshan (00874) announced that recently, Baiyunshan Heji Pharmaceutical Factory, a subsidiary of the company's Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., received the "Drug Supplemental Application Approval Notice" issued by the National Medical Products Administration. The drug's common name is Koujie Spray.

Guangzhou Baiyunshan Pharmaceutical Holdings (00874) announced that its subsidiary, Guangzhou Baiyunshan Pharmaceutical Holdings Medical Group Co., Ltd., has received a "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration for the drug "Koujie Spray." Koujie Spray is used for oral ulcers, gum, and throat pain. As of the date of this announcement, Guangzhou Baiyunshan Pharmaceutical Holdings Medical Group Co., Ltd. has invested a total of approximately RMB 2.4136 million in research and development expenses for the Koujie Spray project (unaudited). According to data from the Minet website, the sales of Koujie Spray in the domestic market in 2024 are estimated to be RMB 50.64 million. In 2024, the sales revenue for this drug from the Guangzhou Baiyunshan Pharmaceutical Holdings Medical Group Co., Ltd. is expected to be RMB 18.94 million.

On February 10, BAIRONG-W (06608) spent approximately HK$11.836 million to repurchase 104,000 shares.

PRU (02378) spent GBP 4.5265 million on February 9 to buy back 38,400 shares.

Shiyue Daotian (09676) spent 4.0316 million Hong Kong dollars on February 10 to repurchase 450,000 shares.

On February 10, BAIRONG-W (06608) spent approximately HK$11.836 million to repurchase 104,000 shares.

PRU (02378) spent GBP 4.5265 million on February 9 to buy back 38,400 shares.

Shiyue Daotian (09676) spent 4.0316 million Hong Kong dollars on February 10 to repurchase 450,000 shares.